Synthesis and G-Quadruplex-Binding Properties of Defined Acridine Oligomers by Ferreira, Rubén et al.
SAGE-Hindawi Access to Research
Journal of Nucleic Acids
Volume 2010, Article ID 489060, 10 pages
doi:10.4061/2010/489060
Research Article
Synthesisand G-Quadruplex-BindingPropertiesof
DeﬁnedAcridineOligomers
Rub´ enFerreira,1 AnnaAvi˜ n´ o,1 Ricardo P´ erez-Tom´ as,2 RaimundoGargallo,3
andRamon Eritja1
1Institute for Research in Biomedicine, IQAC-CSIC, CIBER-BBN Networking Centre on Bioengineering,
Biomaterials and Nanomedicine, Ediﬁci Helix, Baldiri Reixac 15, 08028 Barcelona, Spain
2Cancer Cell Biology Research Group, Department of Pathology and Experimental Therapeutics, Faculty of Medicine,
University of Barcelona Campus Bellvitge, Feixa Llarga, L’Hospitalet de Llobregat, 08907 Barcelona, Spain
3Department of Analytical Chemistry, University of Barcelona, Diagonal 647, 08028 Barcelona, Spain
Correspondence should be addressed to Ramon Eritja, recgma@cid.csic.es
Received 14 January 2010; Revised 22 March 2010; Accepted 13 April 2010
Academic Editor: Daniela Montesarchio
Copyright © 2010 Rub´ en Ferreira et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The synthesis of oligomers containing two or three acridine units linked through 2-aminoethylglycine using solid-phase
methodology is described. Subsequent studies on cell viability showed that these compounds are not cytotoxic. Binding to several
DNA structures was studied by competitive dialysis, which showed a clear aﬃnity for DNA sequences that form G-quadruplexes
and parallel triplexes. The ﬂuorescence spectra of acridine oligomers were aﬀected strongly upon binding to DNA. These spectral
changes were used to calculate the binding constants (K). Log K were found to be in the order of 4–6.
1.Introduction
Small organic molecules with speciﬁc interactions with DNA
have become antitumor, antiviral, and antibiotic drugs [1,
2]. Duplex DNA-binding drugs interact in two main ways,
through groove binding and through intercalation. Medic-
inal chemistry has made a considerable eﬀort in searching
for and testing of a large number of drugs with increased
selectivity to a range of DNA sequences or structures. More
recently, some of this interest has moved to the search of
new ligands for G-quadruplexes [3]. This structure motif is
formed by the planar association of four guanines in a cyclic
Hoogsteen hydrogen bonding tetrad.
Guanine-rich sequences form G-quadruplex structures
and have been found in telomeres [4] and in transcriptional
regulatory regions of critical oncogenes such as c-myc and
c-kit [5, 6]. Ligands that selectively bind and stabilize these
structures have become anticancer drugs of interest [7].
The G-quadruplex stabilization occurs in most cases
by π-π stacking and electrostatic interaction. G-quadruplex
ligands are normally planar aromatic molecules that are
prone to stacking with G-tetrads. Some of them are also
positively charged or have hydrophilic groups to favor
electrostatic interaction [8].
Although there is a long way to go in the develop-
ment of potent drugs that target G-quadruplexes, some
promising lead compounds have been achieved [9]. Several
ligand structures have been studied, such as anthraquinones,
cationic porphyrins, perylene derivatives, and a large num-
ber of compounds [9]. Among the acridine compounds,
3,6,9-trisubstituted acridines have inhibitory activity in the
nanomolar range and they have entered preclinical studies
[8, 10, 11].
In previous studies we described the preparation of
sequence speciﬁc oligomers of DNA-intercalating drugs
using protocols based on solid-phase synthesis in an attempt
to facilitate the preparation of compounds with improved
DNA-binding selectivity [12, 13]. It has been proposed that
bis- and tris-intercalating drugs show promising activity and
selectivity [14, 15]. Here we described solid-phase synthesis
protocols for the preparation of several acridine oligomers
linked through 2-aminoethylglycine units as well as their
DNA-binding properties. Although the acridine derivatives
described in this study are not cytotoxic, they show a clear2 Journal of Nucleic Acids
Table 1: Sequences of oligonucleotides.
No. Name Sequence (5 –3 )
1 T20 TTT TTT TTT TTT TTT TTT TT
2 24bclc CCC GCC CCC TTC CTC CCG CGC CCG
3 Dickerson CGC GAA TTC GCG
4 Ds26 CAA TCG GAT CGA ATT CGA TCC GAT TG
5 GA triplex GAA AGA GAG GAG GCC TTT TTG GAG GAG AGA AAG + CCT CCT CTC TTT C
6 TC triplex CCT CCT CTC TTT CCC TTT TTC TTT CTC TCC TCC + GAA AGA GAG GAG G
7 TG4T TGG GGT
8 TBA GGT TGG TGT GGT TGG
9 HT24 TAG GGT TAG GGT TAG GGT TAG GGT
10 24bcl CGG GCG CGG GAG GAA GGG GGC GGG
11 cmyc GGG GAG GGT GGG GAG GGT GGG GAA GGT GGG G
aﬃnity for several DNA G-quadruplex structures, especially
those sequences found in the promoter regions of c-myc [16]
and bcl-2 [17, 18]o n c o g e n e s .
2.MaterialsandMethods
2.1.Chemicals. Thephosphoramiditesandancillaryreagents
used during oligonucleotide synthesis were obtained from
Applied Biosystems (USA) and Link Technologies Ltd.
(Scotland). The rest of the chemicals were purchased
from commercial sources. The Slide-A-Lyzer Mini Dial-
ysis Units 3500MWCO were purchased from Pierce.
Acridine-9-carboxylic acid was obtained from Aldrich. 2-
(Acridine-9-carboxamide)acetic acid was prepared by reac-
tion of acridine-9-carboxylic acid with glycine methyl
ester and subsequent saponiﬁcation of the methyl ester
as described [10]. Boc-(2-aminoethyl)glycine(Fmoc) (Boc-
Aeg(Fmoc)-OH) was obtained from Iris Biotech and Fmoc-
glycine (Fmoc-Gly-OH) was obtained from Bachem. Boc-6-
aminohexyl hemisuccinate was prepared by reaction of Boc-
6-aminohexanol with succinic anhydride.
2.2. Oligonucleotide Synthesis. Oligonucleotide sequences
(Table 1) were prepared on an automatic Applied Biosystems
3400 DNA synthesizer on 1μmoL (CPG resin) scale using
commercially available 2-cyanoethyl phosphoromidites.
After the assembly of the sequences, oligonucleotide-
supports were deprotected using 32% aqueous ammonia
at 55◦C for 16h. Ammonia solutions were concentrated to
dryness and the residue was desalted by a NAP-10 (Sephadex
G-25)c o l u m n .
2.3. Solid-Phase Synthesis of Acridine Oligomers. Acridine
dimers and trimers (1–4, Figure 1) were prepared with
the 2-aminoethylglycine scaﬀold, which allows the growth
of a polyamide skeleton on solid-phase and the following
incorporation of acridine unit.
Theassemblyof2-aminoethylglycinederivativeswascar-
ried out on methylbenzhydrylamine (MBHA) polystyrene-
1%-divinylbenzene solid support applying an Fmoc/Boc
hybrid strategy using Boc-Aeg(Fmoc)-OH, Fmoc-Gly-OH,
and acridine-9-carboxylic acid as building blocks (Figure 2).
Fmoc-Sarcosine-OH (5eq) was coupled to the resin
using standard coupling conditions (5eq. PyBOP and 10eq.
DIEA, 1h), then the Fmoc group was removed (20% of
piperidine in DMF, 30min), and Boc-6-aminohexyl hemi-
succinate (Boc–NH–(CH2)6–OCOCH2CH2COOH) was
coupled (5eq R-COOH, 5eq. PyBOP and 10eq. DIEA, 1h)
to the support. The residual unreacted amino groups were
acetylated with 5eq. of acetic anhydride and 5eq. of DIEA.
Next, the Boc group was removed (40% triﬂuoroacetic
acid in dichloromethane) and the 2-aminoethylglycine
skeleton was synthesized by repetitive couplings of Boc-
Aeg(Fmoc)-OH until reaching the desired dimer or trimer
compound. The last Boc group of the sequence was removed
and the resulting amino group was acetylated (5eq. acetic
anhydride and 5eq. DIEA).
Once the aminoethylglycine backbone was built, the
Fmoc-protecting groups of the side chains were removed
(20% of piperidine in DMF, 30min), and Fmoc-Gly-
OH followed by 9-acridine carboxyl acid was coupled to
the support. The progress of the coupling reactions was
followed by ninhydrine test and by UV monitoring of the 9-
methylene-9H-ﬂuorene released during deprotection, which
allowed optimization of the coupling conditions.
The acridine dimer 1 and trimer 3 were obtained
by treatment of the appropriate solid supports with HF
a n h y d r o u sa t0 ◦C. Finally the acridine dimer 2 and trimer
4 were obtained by treatment of dimer 1 and trimer 3
respectively with 32% aqueous ammonia (1h, 55◦C).
Good yields and purities were obtained for the products
(around 85% for 1 and 2, 75% for 3 and 4). HPLC and
MALDI-TOF spectra are shown in Supplementary Material
available onlie at doi: 10.4061/2010/489060.
The compounds were analyzed by MALDI-TOF, 1
[M+Na+] = 1080.3 (expected 1054.2), 2 [M] = 885.2
(expected 884.0), 3 [M] = 1418.9 (expected 1416.5), and 4
[M] = 1247.4 (expected 1246.4). MALDI-TOF spectra were
obtained using a Perseptive Voyager DETMRP mass spec-
trometer,equippedwithnitrogenlaserat337nmusinga3ns
pulse. The matrix used contained 2,5-dihydroxybenzoic acid
(DHB, 10mg/mL in water).
Analytical HPLC was performed using XBridge OST C18
(Waters), 2.5μm, 4.6 × 50mm column using a 10-minuteJournal of Nucleic Acids 3
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Figure 1: Structure of the acridine derivatives prepared.
linear gradient from 9% to 45% B, ﬂow rate 1mL/min;
solution A was 5% ACN in 0,1M aqueous TEAA, and B 70%
ACNin0.1MaqueousTEAA.HPLCchromatogramsandMS
spectra can be found in Supplementary Material.
FluorescencespectrawererecordedusingaJascoFP-6200
spectroﬂuorometer equipped with a Peltier temperature
controller, λem =435nm (λexc = 252nm).
UV spectra were recorded using a Jasco spectrophotome-
ter V-650, λmax = 252nm, 360nm.
2.4. Cell Viability Assays. The in vitro cytotoxicity of the
compounds (Figure 1) was evaluated by colorimetric assays
with tetrazole salts (MTT) on Jurkat clone E6-1 (human
leukemia), GLC-4 clone (human lung carcinoma) cell lines,
and one mouse ﬁbroblast cell line (NIHT-3T3).
GLC4 and Jurkat cell lines were cultured in RPMI and
NIH3T3 in DMEM and supplemented with 10% fetal calf
serum, 10000u/mL penicillin, 10μg/mL streptomycin and
200mM L-glutamine. Cells were grown in a humidiﬁed
atmosphere of air containing 5% CO2 at 37◦.C e l l sw e r e
plated in triplicate wells (1.5·104 cells well) in 100μL
of growth medium in 96-well plates and proliferate for
24h and then treated with increasing concentrations of
acridine oligomers. After 72h of incubation, 10μMo fM T T
(5mg/mL in Phosphate buﬀer saline 10%) was added for
an additional 4h. The absorbance at 570nm was measured
on a multiwell plate reader after addition of 100μlo f
isopropanol:1N HCl (24:1). Cell viability was expressed
as a percentage of control and IC50 was determined as the
concentration of drug that produced a 50% reduction of
absorbance at 570nm.
2.5. Competitive Dialysis Assays. 100μLo fa5 0μM oligonu-
cleotide (Table 1) in potassium phosphate buﬀer (185mM
NaCl, 185mM KCl, 2mM NaH2PO4, 1mM Na2EDTA,
6mMN a 2HPO4 at pH 7) was introduced into a separated
dialysis unit. A blank sample containing only buﬀer without
oligonucleotide was also prepared. All 12 dialysis units were
then placed in the beaker containing the 1μMs o l u t i o n
of the appropriate acridine derivative. The samples were
allowed to equilibrate with continuous stirring at room
temperature overnight. After the equilibration period, DNA
samples were removed to an Eppendorf tube. SDS is usually
added to denature the DNA sample and release the acridine
oligomer, but in our case the presence of K+ ions induced the
formation of a white precipitate, which interfered with the
measurement of the ﬂuorescence spectra of the samples.
In order to measure the compound retained in the
dialysis unit, samples were treated with snake-venom phos-
phodiesterase to degrade the DNA and release the acridine
oligomer. 350μL of potassium phosphate buﬀer (without
EDTA), buﬀer at pH 8.5, 50μL of 100mM MgCl2,a n d
1μmofsnakevenomphosphodiesterasesolutionwereadded
for an additional overnight incubation at 37◦C. Finally, the
ﬂuorescence of each sample was measured (λex and λem were
set to 252 and 435nm, resp.).
2.6.FluorescenceAssays. Thestudyoftheinteractionequilib-
rium of acridine derivatives and oligonucleotides consists of
recording the ﬂuorescence spectra of a 0.2μMs o l u t i o no ft h e
acridine derivative after the addition of increasing amounts
ofoligonucleotide(from0to10μM)inpotassiumphosphate
buﬀer (185mM NaCl, 185mM KCl, sodium phosphate,
1mM EDTA, pH 7). These experiments were carried out by
adding small volumes of an oligonucleotide stock solution
to the 0.2μM solution of the acridine derivative. After 24h
the emission spectra of the resulting solutions were recorded
from300to500nmat252nmexcitationwavelengthat25◦C.
The macroscopic binding constant (K) corresponding to
the reaction
DN A+li gan d − − → ← Interaction complex (1)4 Journal of Nucleic Acids
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Figure 2: Solid-phase synthesis of dimer and trimer acridine derivatives. (a) (i) Fmoc-Sar-OH, PyBOP, DIEA; (ii) 20% piperidine, DMF;
(iii) Boc–NH–(CH2)6–OCH2CH2COOH, PyBOP, DIEA; (b) (i) 40% TFA, DCM; (ii) Fmoc-Aeg(Boc)-OH, PyBOP, DIEA; (iii) Repeat steps
(i) and (ii) n times; (c) (i) 40% TFA, DCM; (ii) Ac2O, DIEA, DMF; (d) (i) 20% piperidine, DMF; (ii) Fmoc-Gly-OH, PyBOP, DIEA; (e) (i)
20% piperidine, DMF; (ii) acridine-9-carboxylic acid, PyBOP, DIEA; (f) anhydrous HF (0◦); (g) 32% aqueous NH3.
was calculated from the multivariate analysis of ﬂuorescence
data recorded in the range 300–390nm using the hard-
modeling program Equispec [19]. This program performs a
nonlinear least squares optimization of K and of the pure
ﬂuorescence spectra corresponding to each of the species
considered (DNA, ligand, and interaction complex). A 1:1
stoichiometry DNA:ligand for the interaction complex was
assumed. The logarithms of the binding constants calculated
are given as their weighted means with twice their standard
errors (units of the least signiﬁcant digit). Results are shown
in Table 2.
2.7. Circular Dichroism. An increasing amount of 1 (from
0t o8μM) in potassium phosphate buﬀer (185mM NaCl,
185mM KCl, sodium phosphate, 1mM EDTA, pH 7) was
added to a 1μM solution of the oligonucleotide. The
CD spectra were recorded after 24h on a Jasco J-810
spectropolarimeter attached to a Julabo F/25HD circulating
water bath in 1cm path-length quartz cylindrical cells, using
a 50 nm/min scan rate, a spectral band width of 1nm, and
a time constant of 4s. All the spectra were corrected with
the buﬀer blank, normalized to facilitate comparisons and
noise-reduced using Matlab software. CD spectra are shown
as supplementary data.
3. Results and Discussion
3.1.SynthesisofAcridineOligomers. Thesynthesisofacridine
dimer and trimers has been described previously [13]
using a Boc-(2-aminoethyl)glycine derivative carrying theJournal of Nucleic Acids 5
Table 2: Logarithm of the binding constants (log K) calculated from data recorded throughout ﬂuorescence titrations using Equispec
program assuming a 1:1 stoichiometry DNA:ligand for the interaction complex (details in materials and methods). Compounds 1–4
correspond to the acridine dimers and trimers prepared in this study. HT24, 24bcl, cmyc, and Dickerson correspond to oligonucleotide
sequences shown in Table 1.
1234
HT24 4.9 ± 0.4 4.6 ± 0.5 5.3 ± 0.3 n.d.
24bcl 6.8 ± 0.5 5.1 ± 0.1 5.3 ± 0.2 n.d.
cmyc 5.5 ± 0.3 4.9 ± 0.2 4.8 ± 0.5 5.3 ± 0.2
Dickerson n.d. n.d. n.d. n.d.
n.d. not determined.
2-(acridine-9-carboxamide)acetyl residue. The synthesis of
this monomer was long and yields were low.
An alternative method developed is to ﬁrst assemble
the Boc-(2-aminoethyl)glycine backbone on solid-phase,
and then the intercalating agent is added. This strategy is
more convenient for rapid synthesis, as it is unnecessary to
construct each intercalating monomer.
Thus, acridine oligomers were assembled using the
methylbenzhydrylamine (MBHA) resin by applying an
Fmoc/Boc hybrid strategy and using Boc-(2-aminoethyl)-
(Fmoc)glycine [Boc-Aeg(Fmoc)-OH] as building block
(Figure 2).TheBocgroupwasusedtoprotecttheaminoethyl
group of each unit, which thus facilitated elongation of
the backbone. Fmoc was the semipermanent protecting
group for the amino group of glycine through which the
intercalating compound was introduced. The succinyl linker
was selected to connect the solid support and the oligomer.
This linker is used in oligonucleotide synthesis and it is labile
toammonia.Unfortunately,thelinkerisnotcompatiblewith
Fmocchemistry.Ithasbeendescribedthatanintramolecular
side reaction can lead to premature loss of the oligomers
during the base treatment used to remove the Fmoc group
[20]. Thus, N-methylglycine (sarcosine) was incorporated
between the amino-support and the succinyl linker. The
presence of the N-methyl group prevents the potential side
reaction [20]. 6-Aminohexanol was used to connect the
succinyl linker and the oligomer backbone, as described for
the synthesis of peptide nucleic acid (PNA) oligomers [21].
The (2-aminoethyl)glycine backbone was assembled by
consecutive additions of Boc-Aeg(Fmoc)-OH to obtain the
dimer and trimer sequence. Acetylation of the N-terminal
position was carried out using acetic anhydride and a base.
Next, the removal of the Fmoc group allowed the
addition of a Fmoc-glycine unit as a spacer, which was
followed by the addition of acridine-9-carboxylic acid. The
acridine dimer and trimer were synthesized in this way
(Figure 2).
After assembly of the oligomers, the resulting supports
were treated with ammonia. The desired oligomers were
not released from the support even after prolonged time
and high temperatures. We therefore treated the supports
with anhydrous HF to yield the acridine oligomers 1 and
3, which contain the sarcosyl succinyl linker. At this point
HPLC spectra showed a major peak that had the expected
molecular weight for the oligomers 1 and 3 carrying the
sarcosyl succinyl linker (see supplementary data). This
observation indicates that the simultaneous incorporation
of all acridines proceeded with excellent yields. Ammonia
treatment of acridines 1 and 3 in solution now yielded the
desired acridine dimer 2 and trimer 4 in excellent yields and
purity (see supplementary data). Compounds 1–4 were fully
characterized and their properties were analyzed.
ThepKaoftheacridineringofacridine-9-carboxylicacid
and 2-(acridine-9-carboxamide)acetic acid was measured by
UV titration. pKa of acridine-9-carboxylic acid was 5.5 ±
0.1 and 2-(acridine-9-carboxamide)acetic acid 4.1 ± 0.2. We
thereforeestimatedthattheacridineringsofcompounds1–4
are mainly unprotonated at pH 7.0.
3.2. Cell Viability Assay. The in vitro cytotoxicity of the com-
pounds was evaluated by colorimetric assays with tetrazole
salts (MTT). This assay is based on the capacity of living
cells to incorporate and reduce MTT. This reaction can be
followed by the change of absorbance of the reduced and
oxidized forms. This reaction is done by the action of the
mitochondrial enzyme succinatehydrogenase, which is active
onlyinlivingcells.Theintensityofcolorisdirectlycorrelated
with the number of living cells in the sample. No cytotoxicity
a c t i v i t yw a so b s e r v e di nc o m p o u n d s1–4 at concentrations
up to 50μM.
3.3. Competitive Dialysis Studies. In order to evaluate the
selectivity of the compounds for DNA structures, a compet-
itive dialysis experiment was performed using 11 oligonu-
cleotides (Table 1) representing several nucleic acid struc-
tures [22]. The more acridine accumulated in the dialysis
unit indicates a higher binding aﬃnity to the oligonucleotide
present in the dialysis unit. As model for single stranded
structureswe used T20 and the C-rich complementary strand
of bcl-2 (24bclc). This last oligonucleotide folds in an i-form
quadruplex structure at acidic pH but has no structure in
the conditions used in the dialysis (pH 7) [18]. As duplexes
we used the self-complementary sequences Dickerson-Drew
dodecamer (Dickerson) and a 26 mer (ds26). A parallel
triplex (TC triplex) and an antiparallel triplex (GA triplex)
were also prepared by mixing a hairpin Watson-Crick
sequence and the corresponding triplex-forming sequence.
Finally, the following G-quadruplex sequences were pre-
pared: the tetramolecular parallel G-quadruplex TG4T[ 23],
the antiparallel thrombin-binding aptamer (TBA) [24], the
human telomere sequence (HT24) [25], and the promoter
sequences of c-myc (cmyc) [16]a n dbcl-2 (24bcl) [17, 18].6 Journal of Nucleic Acids
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Figure 3:Resultsobtainedbythecompetitivedialysisassay.TheamountofligandboundtoeachDNAstructureisshownasabargraph.The
ﬂuorescence of each sample was measured using an excitation wavelength of 252nm and an emission wavelength of 435nm, respectively.Journal of Nucleic Acids 7
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Figure 4: Fluorescence titration spectra. Fluorescence spectra of a 0.2μM solution of the acridine derivative after the addition of increasing
amounts of oligonucleotide (from 0 to 10μM) in potassium phosphate buﬀer. Excitation wavelength is 252nm.
We used the protocol described by Ren and Chaires
[26] with a few modiﬁcations. The buﬀer solution was
similar to that described in [26]b u tK + was included
(185mM) to ensure the formation of the most stable G-
quadruplex structures. At the end of the dialysis experiment,
the amount of acridine derivative bound to the DNA
was analyzed by ﬂuorescence measurement of the acridine
compound. After dialysis, we observed that the spectra of
the acridine derivatives of some samples (especially those
from G-quadruplexes) diﬀered greatly from the ﬂuorescence
spectraoftheinitialcompounds.Thisdiﬀerenceisattributed
to the interaction of the acridine derivatives with the G-
quadruplex. In order to release the acridine oligomer, the
addition of SDS is recommended [26, 27]. Using SDS, the
presence of K+ ions resulted in the formation of a white
precipitate with SDS which did not allow the measurements
of the ﬂuorescence spectra [27]. In order to solve this
problem, the oligonucleotide was digested with snake venom
phosphodiesterase at the end of the dialysis experiment.
Thus, the ﬂuorescence spectra of the acridine derivatives
were recorded with high accuracy without the interference
of DNA and without the use of SDS.
We measured the binding preferences of compounds 1–4
and the acridine monomers acridine-9-carboxylic acid and
2-(acridine-9-carboxamide)acetic acid (Figure 1). Acridine-
9-carboxylic acid showed aﬃnity only for duplex ds26
(Figure 3). Unexpectedly, the addition of the glycine residue,
used as spacer, induced a change in the aﬃnity. 2-(Acridine-
9-carboxamide)aceticacidshowedthehighestaﬃnityforthe
G-quadruplex sequences cmyc and 24bcl and less aﬃnity for
duplex ds26.
Dimer 1 (dimer with the sarcosylsuccinyl linker) has a
similar proﬁle as 2-(acridine-9-carboxamide)acetic acid. In
this case, the G-quadruplex 24bcl is preferred to the cmyc8 Journal of Nucleic Acids
sequence. Some aﬃnity for the TC triplex is observed but no
aﬃnity for duplex ds26. Surprisingly, dimer 2 (without the
sarcosylsuccinyl linker) lost most of the selectivity although
some residual higher aﬃnity for G-quadruplex 24bcl was
observed.
In contrast, trimer 3 (trimer with the sarcosylsuccinyl
linker) presented lower binding aﬃnity than the other
c ompounds.H o w ev er ,trimer4(withoutthesarcosylsuccinyl
linker) recovered most of the aﬃnity for 24bcl and cmyc
showing a similar proﬁle to that observed for dimer 1.
3.4. Measurement of G-Quadruplex-Aﬃnity Constants by
Fluorescence Spectroscopy. Dialysis experiments suggest that
someoftheacridinederivativespreparedhavespecialaﬃnity
for 24bcl and cmyc G-quadruplexes. In order to conﬁrm this
observation, binding constants were estimated using mole-
ratioexperimentsmonitoredwithﬂuorescencespectroscopy.
Hence, increasing amounts of oligonucleotides 24bcl, HT24,
cmyc, and Dickerson were added to a solution with a
ﬁxed concentration of the acridine derivatives, and the
ﬂuorescence spectra were recorded at excitation wavelengths
252 and 360nm.
At both wavelengths, changes in the ﬂuorescence spec-
tra upon the addition of oligonucleotides were observed.
Figure 4 shows the changes in the ﬂuorescence spectra of
acridine dimer 1 at excitation wavelengths 252nm when
oligonucleotides 24bcl, HT24, cmyc, and Dickerson were
added. A dramatic increase in ﬂuorescence intensity was
observed around 360nm upon addition of G-quadruplex
DNA sequences (24bcl, HT24, and cmyc). The greatest
changes were seen with 24bcl and cmyc. Similar results
were found with compounds 2, 3,a n d4 as well as
2-(acridine-9-carboxamide)acetic acid (see supplementary
data). Interestingly, when the Dickerson dodecamer was
added, no changes in the ﬂuorescence spectra were detected.
The progressive modiﬁcation of the ﬂuorescence spectrum
of these compounds reﬂects their interaction with the G-
quadruplex.
Fluorescencedataobtainedatanexcitationwavelengthof
252nm were analyzed with the hard-modelling EQUISPEC
program in order to calculate the corresponding binding
constants (Table 2). The values of the logarithm of the bind-
ing constant (logK) obtained lie in the range 4–6, suggesting
a weak interaction with DNA. Of all the compounds, dimer
1 showed the highest binding constants, thereby suggesting
a stronger interaction with DNA than the other compounds
studied. However these values were slightly lower than the
binding constants calculated for other similar ligands, such
as the acridine monomers BRACO-19 (logK = 7.4) and
BSU6048 (logK = 6.5) [28] or a hemicyanine-peptide ligand
(logK = 7.1 [29]), when interacting with human telomere
quadruplex.
Changes in the ﬂuorescence spectra at an excitation
wavelength of 360nm were also recorded. Fluorescent emis-
sion at this wavelength 360nm was much lower than that
recorded at 252 nm; so the ﬂuorescent signal was low. Upon
addition of the oligonucleotide to a solution of compounds
1–4, the formation of a new maximum at 442nm was
observed(seesupplementarydata).Althoughtheﬂuorescent
intensity was low, we could estimate the binding constant of
the stronger interactions of compound 1 with 24bcl (7.2 ±
0.4)andcmyc(5.5±0.2)sequences(seesupplementarydata).
These values are in agreement with those recorded at an
excitation wavelength of 252nm (Table 1).
Finally, CD spectra of the DNA:ligand mixtures showed
no signiﬁcant diﬀerences in relation to those of DNA (see
supplementary data). This observation suggests that the
DNA G-quadruplex structure is not altered signiﬁcantly
upon binding of the acridine derivatives.
4. Conclusions
I ns u m m a r y ,h e r ew eh a v ed e s c r i b e dan e wo p t i m i z e d
protocol for the synthesis of acridine oligomers with a (2-
aminoethyl)glycine backbone. In this method, the Boc-(2-
aminoethyl)glycine backbone is ﬁrst assembled on solid-
phase, and then the intercalating agent is assembled on the
b a c k b o n e .T h i ss t r a t e g yi sf a s t e ra n dm o r ee ﬃcient than
the one described previously [13] and yields the desired
oligomers with good yields. A succinyl linker was used to
connect the oligomers to the solid support. The succinyl
linker attached to sarcosine was unexpectedly too stable and
oligomers could not be directly released from the support by
a single ammonia treatment. Instead a two-step protocol was
used obtaining the desired compounds and an intermediate
oligomer carrying a long succinyl sarcosine chain at the C-
terminal position.
Competitive dialysis experiments have shown diﬀerences
on the aﬃnity of acridine oligomers to G-quadruplexes.
Higher aﬃnities are found in G-quadruplex sequences
present on the promoter regions of c-myc and bcl-2 onco-
genes. This aﬃnity is modulated by the number of acridines
and the presence of the succinyl sarcosine chain at the C-
terminal position, dimer 1 and trimer 4 being the more rele-
vant compounds for G-quadruplex binding. The monomer
2-(acridine-9-carboxamide)acetic acid also shows binding
properties of interest and it is the simplest compound to
be prepared. Unfortunately, the compounds synthesized in
this study did not have antiproliferative activity in spite
of their aﬃnity to quadruplex. This observation contrasts
withotherreportedquadruplex-bindingacridinederivatives,
such as BRACO-19 [11, 30] which shows anticancer activity.
The lower aﬃnity to telomere G-quadruplex sequence and
the larger size of the acridine derivatives described in the
present study may hinder cellular uptake and may explain
the absence of antiproliferative activity.
The acridine nucleus is described to interact to G-
quadruplex. Depending on the substituents, the acridine
nitrogen can be charged when bound to DNA, and with the
ring stacked on a G-tetrad, the charge will occupy a position
similar to that of the potassium cation that stabilizes the G-
quadruplex [28]. The introduction of protonable side chains
on the acridine ligand enhances binding by electrostatic
interactions[28].Inourcasetheacridineshadnoprotonable
substituents and the acridine nitrogen was not charged when
bound to DNA. For this reason, the aﬃnity of oligomeric
acridines to G-quadruplexes is due to the multimeric nature
of the compounds as well as the addition of a glycineJournal of Nucleic Acids 9
to acridine-9-carboxylic acid. An interesting possibility for
future development is the introduction of protonable sites
at the oligomeric acridines, which may increase solubility
in water, aﬃnity to target, and cellular uptake. The method
describedherewillcontributetoacceleratingthepreparation
of potential active oligomeric compounds.
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